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The nuclear DNA content of 98 operable breast cancers was determined by flow 
cytometric analysis using paraffin-embedded tissue. All patients were on follow-up 
and failure of treatment or recurrences were identified. DNA ploidy data in the 
form of ploidy status and DNA index (DO has been correlated with various clinical 
and histopathologic factors. The only significant correlation using univariate 
analysis exists between the histologic grade and DI (P < 0.025), recurrence of the 
disease and ploidy status ( P  < 0.005), and recurrence of the disease and DI 
( P  < 0.005). The absence of correlation of ploidy status with other tumor derived 
factors indicates the independent nature of ploidy as a prognostic factor. 
Multivariate analysis showed that in the whole-group ploidy (P < 0.01), tumor 
margin (P < 0.01), and menopausal status ( P  < 0.01) were significant factors in the 
order mentioned. DI with a cut of at 1.29 is not found to be a significant factor in 
the multivariate analysis. The maximum prognostic value of ploidy status was 
observed in the postmenopausal group (P < 0.0005). In the node-negative group 
ploidy status (P < 0.05) is the only independent significant factor predicting for 
early relapse. It is concluded that ploidy status is an independent prognostic factor 
predicting for recurrence of the disease. In the node-negative subgroup this could 
be used to identify the subset of patients who may benefit from adjuvant treatment. 
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REAST CANCER is a heterogeneous disease. Even in B the same clinical stage, different patients behave dif- 
ferently. There is thus a need to determine significant 
prognostic factors, for deciding appropriate therapy in a 
given case. 
Axillary lymph node status is one of the important 
prognostic factor in patients with breast cancer.' Patients 
with node-negative tumors have better survival compared 
with patients where lymph nodes are involved. However, 
it has been reported that approximately 30% of node-neg- 
ative patients recur and die within 10 years. A prognostic 
marker that could identify this high-risk subgroup among 
node-negative patients would be of great value in indi- 
vidualizing therapy. 
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The nuclear DNA content has recently emerged as a 
new prognostic indicator in breast Using flow 
cytometric study, thousands of nuclei can be evaluated 
for their DNA content with a good resolution. Presence 
or absence of an aneuploid peak and the S-phase fraction 
are of prognostic Breast carcinomas with a non- 
diploid or aneuploid nuclear DNA content are associated 
with less favorable prognosis compared with tumors with 
a diploid DNA content. It is this determination of biologic 
aggressiveness and cell proliferation kinetics that makes 
ploidy analysis an important parameter affecting tumors 
of all sizes and stages. 
The use of paraffin-embedded tissues for DNA analysis 
is a new technique.' The advantage of using archival 
blocks for DNA analysis is that a long follow-up is avail- 
able and the DNA ploidy pattern can be analyzed in that 
context. There is, however, no consensus about how the 
DNA histograms should be analyzed. Various groups have 
used different classification to analyze the DNA histo- 
grams, keeping in view the presence or absence of aneu- 
ploid peaks and percent S-phase fraction. Due to inter- 
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observer variation in interpretation and different com- 
puter programs used to find S-phase, comparison between 
different studies where percent S-phase has been calculated 
is not possible. DNA index (DI), which is the ratio of the 
mean fluorescence channel of the aneuploid peak to that 
of the Gl/GO peak, allows better assessment of the his- 
tograms. '' 
The current study analyzes the DNA ploidy patterns 
from paraffin-embedded tissues of patients with breast 
cancer. The ploidy data has been correlated with various 
other histopathologic and clinical parameters. The prog- 
nostic significance of DNA ploidy in various subgroups 
using multivariate analysis has been studied. 
Patients and Methods 
Patients with breast cancer, who had been treated with 
radical or modified radical mastectomy and were being 
observed at the Breast Cancer Clinic, were taken up for 
the study. Detailed clinical data, recorded at the time of 
surgery, was obtained from their records. Patients with 
axillary lymph node involvement received six cycles of 
adjuvant chemotherapy" in the form of cyclophospha- 
mide, methotrexate, and 5-fluorouracil (CMF). Node- 
negative patients were observed with no adjuvant therapy. 
All patients were managed with the above-mentioned 
protocol. 
Of 152 operable patients with breast cancer registered 
at the breast cancer clinic during the period 1980 to 1987, 
complete data with follow-up was available for 108 pa- 
tients. Paraffin-embedded blocks were available for 104 
patients. In 6 cases the DNA histogram was uninterpret- 
able; the data presented here concern 98 patients. 
For the first 2 years after definitive surgery the patients 
were observed at 3-month intervals, after which the pa- 
tients were examined at 6-month intervals. Chest radio- 
graphs and serum alkaline phosphatase tests were done 
at each follow-up visit. Computed tomography (CT) and 
radionuclide scans were done in selected cases, depending 
upon the degree of suspicion. Chest wall and regional 
lymph node recurrences were confirmed histologically 
using fine-needle aspiration. 
A detailed histopathologic examination of mastectomy 
specimen was carried out in all cases. Histologic grading 
was done by the criteria proposed by Bloom and Rich- 
ardson. '* The various histologic parameters analyzed were 
histologic grade, histologic type, nuclear grade, tumor 
margin, tumor necrosis, lymphatic and blood vessel in- 
vasion. It was assessed whether there was a tumor infil- 
tration for the lymph nodes, and also for the presence or 
absence of sinus histiocytosis and germ cell hyperplasia. 
Measurement of Nuclear DNA Content 
Fifty-micron-thick sections were taken from the paraffin 
block, which had a substantial tumor area. The sections 
were dewaxed, rehydrated, and then treated with I %  pep- 
sin solution (pH 1.5) using the technique of Hedley et 
With repeated vortexing a cell suspension was ob- 
tained that was passed through a mesh and then washed 
with saline. Cells were stained using a hypotonic solution 
of propidium iodide (0.05 mg/ml in 1.12% sodium citrate) 
that was added to the cell pellet and kept on ice for 15 
minutes. For controls, paraffin blocks were made from 
normal breast tissue and processed as for tumor samples. 
The histograms obtained from ten different normal breast 
tissues showed the diploid pattern. 
DNA content was measured using FACScan cytometer 
(Becton Dickinson Immunocytometry Systems, Moun- 
tain View, CA). A 488-nm argon laser line run at 15 mW 
was used for fluorescence excitation. A 585 k 22 nm band 
pass filter was used in front of red photomultiplier to block 
the laser light. For each histogram 5000 nuclei were ex- 
amined. The first peak from the left, which corresponds 
to GO/G 1 of the cell cycle, was by convention set at chan- 
nel 50 for all tumors. 
DNA Index Determination 
The degree of DNA content aberration was expressed 
by the DNA index. With this method we have assumed 
that the GO/Gl peak with the smallest DNA content rep- 
resents normal diploid cells in all samples. Tumors with 
a DI of less than 1.0 have been erroneously labeled as 
DI = 1.0. 
Coefficient of variation (CV) of the GO/GI peak varied 
from 3.2 to 7.2 with a mean of 4.4. Tumors with CV over 
8% and those with excessive debris were not included in 
the study (six). Tumors were labeled as diploid when the 
DI was 1. Tumors with a shoulder close to GO/G 1 peak 
were also labeled as diploid. The histogram was classified 
as nondiploid when there were more than one peak or 
multiple peaks. The histograms were analyzed without 
the knowledge of histopathologic findings and clinical 
data. 
Results 
The clinical characteristics of patients studied is shown 
in Table 1. Thirty-six patients had recurrences: 1 1 recur- 
rences were in the chest wall and supraclavicular area, 
and 25 were distant metastasis. Recurrences appeared 
within a mean time interval of 28 months from the date 
of surgery (range, 8 to 60 months). 
DNA Ploidy and Recurrence 
The DNA data has been correlated with recurrence in 
two ways. First, tumors with a single peak have been la- 
beled as diploid (this also includes peaks with a shoulder 
effect); all other tumors with more than one peak have 
been labeled as nondiploid. Second, DI have been cal- 
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TABLE 1. Clinical Characteristics of 98 Patients With Breast Cancer 
Mean age (yr) 
Mean age at menarche (yr) 
Age at 1st child birth (yr) 
Average panty 
Menopausal status 
Premenopausal 
Postmenopausal 
TI 
T2 
T3 
T4 
0 
1-3 
> 4  
Tumor size 
Lymph node involvement 
Failure of treatment 
Locoregional recurrence 
Distant metastasis 
46.93 
14.07 
2 1.93 
3.80 
50 (51.0%) 
48 (49.0%) 
6 (6.0%) 
57 (58.1%) 
29 (29.5%) 
6 (6.0%) 
28 (28.5%) 
30 (30.6%) 
40 (40.8%) 
36 (36.7%) 
1 1  (30.5%) 
25 (69.4%) 
culated and a DI of 1.29 taken as the cutoff value. This 
was calculated after correlating distribution analysis of DI 
with recurrences at various levels of DI. 
Twenty-three of the cancers were diploid (23.4%) and 
75 (76.5%) were nondiploid. The distribution of DNA 
indices with recurrence is shown in Figure 1. In diploid 
tumors the prognosis was favorable (P < 0.0 1) compared 
with the nondiploid group. Cancers with a DI of less than 
1.29 (52) had a favorable prognosis compared with those 
with a DI of more than 1.30 (46) ( P  < 0.01). 
Correlation With Other Prognostic Factors 
Correlation of ploidy and DI with several clinical and 
histopathologic factors using chi-square analysis is shown 
in Table 2. The only significant factors correlating are 
recurrence and histologic grade of the tumor. The age at 
diagnosis also had no impact on the DNA content of the 
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FIG. 1 .  Bar chart showing total number of patients and recurrence in 
various subgroups classified according to diploid or nondiploid status 
and DNA index. 
TABLE 2. Clinicopathologic Features of 98 Patients With Breast 
Cancer and Their Relation to Ploidy and DNA Index 
Nondiploid DNA index 
Feature Percent Percent P > 1.30 Percent P 
Age (v) 
< 49 
> 50 
Menopausal status 
Premenopausal 
Postmenopausal 
TI 
T2 
T3-4 
I 
2 
3 
None 
Present 
Tumor margin 
Circumscribed 
Infiltrative 
Nodal status 
Node negative 
Node positive 
Recurrence 
Absent 
Present 
Tumor size 
Histologic grade 
Tumor necrosis 
59 
41 
5 1  
49 
6 
58 
36 
5 
68 
26 
62 
38 
9 
9 1  
29 
71 
63 
31  
80 
70 
82 
71 
66 
14 
83 
I00 
15 
77 
79 
69 
62.5 
75 
71 
78.5 
65 
94 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
< 0.001 
27 
19 
22 
24 
3 
23 
20 
5 
2 1  
14 
28 
11 
2 
34 
1 1  
35 
22 
24 
46.5 NS 
41.5 
44 NS 
50 
50 
40 NS 
57 
100 
40 <0.025 
53 
49 NS 30.5 
15 
42.5 
39 NS 
50 
35S <0.005 66.6 
NS 
NS: not significant. 
tumor: mean age at diagnosis of patients with a diploid 
tumor was 48.13 years (SD * 8.75) and patients with 
nondiploid tumors, 46.61 years (SD f 10.66). The ages 
of the patients in the node-negative (45.38 years, SD 
f 9.16) and node-positive group (47.03 years, SD f 10.62) 
also were not significantly different. Similarly, there was 
no correlation between menopausal status and ploidy. 
Multivariate Analysis Findings 
Multivariate analysis was done to find out the relative 
importance and the independent nature of the various 
variables. The results of multivariate analysis are shown 
in Table 3. For the whole group the most important in- 
dependent prognostic factors were ploidy (P < 0.00 l), 
type of tumor margin ( P  < 0.01), and menopausal status 
( P  c 0.05). The traditionally established factors like lymph 
node status and histologic grade did not figure as inde- 
pendent factors. Because of the possibility that the prog- 
nostic significance of DNA analysis might be obscured by 
adjuvant therapy, the patients were also stratified on the 
basis of lymph node involvement and menopausal status, 
and then analyzed. 
Discussion 
Indian patients with breast cancer differ from the west- 
ern group of patients because of various clinical charac- 
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TABLE 3. Results of Multivariate Analysis 
Patient group Significant factors (P) R2 (‘70) 
All patients* Ploidy (< 0.001) 
Tm margin (< 0.01) 
Menopausal status (< 0.05) 
Node negative* Ploidy (< 0.05) 
Node positive’ Ploidy (c 0.005) 
Tm margin (c 0.05) 
Menopausal status (< 0.05) 
Premenopausal’ No variables meet the criteria 
Postmenopausal’ Ploidy (< 0.001) 
Tm margin (< 0.05) 
10.0 
7.0 
5.0 
Total (10 Var) (26.0) 
14.4 
Total (9 Var) (36.6) 
8.3 
7.0 
5.0 
Total (9 Var) (27.5) 
24.8 
8 .o 
Total (9 Var) (40.7) 
Var: variable. 
* Dependent variable recurrence. 
teristics. Indian patients have a high parity, early age at 
first childbirth, and are younger14315 (Table 1). Also, be- 
cause patients are younger at the time of presentation, 
the premenopausal and postmenopausal patients are 
nearly equally represented in the group (5 1% versus 4970, 
respectively). The prognostic factors involved may also 
be different. 
Various clinical and histopathologic factors have been 
correlated in the past with an early recurrence of disease 
in breast cancer. As mentioned earlier, of a number of 
histologic parameters studied, lymph node status (P  
< 0.05) and histologic grade (P  < 0.05) correlate signifi- 
cantly with recurrence in univariate analysis (data not 
shown for other parameters). 
S-phase analysis, although reported as a prognostic fac- 
tor, is subject to a lot of variation depending on whether 
fresh tissue or paraffin-embedded tissue is used, with the 
fixed tissue giving rise to a lot of debris and high back- 
ground. A defined aneuploid peak is firm and reproducible 
evidence. The use of DI allows a more objective assess- 
ment of the histogram removing thereby the interobserver 
variation. The DI is easy to calculate and is a reliable 
index. It has been seen that the recurrence rate is higher 
in tumors with higher DI. When the tumors were grouped 
into two groups, DI 1.30 to 1.49 and DI more than 1.50, 
it was found that the recurrence rate was higher in the 
more than 1.50 group (57% versus 48%). The exact sig- 
nificance of this observation is not known. 
Ploidy Analysis as a Unique Prognostic Indicator and 
Its Relationship With Other Factors 
have shown that DNA aneuploidy 
is associated with unfavorable prognosis in breast cancer. 
The association with survival is, however, weak and there 
are some groups that do not show a ~or re l a t ion .~~”~  Ploidy
as an independent prognostic factor has been shown by 
only one group: whereas some have found ploidy signif- 
Most 
icant in a univariate analysis only.’ In this study using 
multivariate analysis we report the ploidy status to be the 
most important independent prognostic factor in the 
whole group, node-negative, node-positive, and post- 
menopausal group of patients (Table 3). 
It is an established fact that nuclear DNA content cor- 
relates with the histologic grading of the tumor, with 
poorly differentiated tumors more likely to be aneu- 
ploid.2,4, 19.20 This is expected as both factors give infor- 
mation regarding the biological aggressiveness and differ- 
entiation of the tumor. In this study the histologic grade 
is the only tumor-derived factor that correlates with the 
DNA content of the tumor. The association of other clin- 
ical and tumor-derived factors with DNA content is con- 
troversial. Whether tumor size should correlate with DNA 
content is also not clear; some groups have shown a cor- 
relation whereas some have n ~ t . ” . ~ ’ . ~ ~  The absence of any 
correlation between DNA content and clinical and tumor- 
derived factors in this series points toward an independent 
nature of DNA content as a prognostic factor and its ca- 
pability to affect prognosis in all groups of patients and 
all sizes of primary lesions. 
Beside histologic grade other factors like tumor margin, 
tumor necrosis, and lymphatic invasion did not correlate 
with the ploidy analysis. Previous studies have, however, 
shown conflicting results regarding the relationship of ax- 
illary nodal status and ploidy a n a l y ~ i s . ’ ~ , ~ ’ . ~ ~  In this study 
no correlation was found between DNA content and 
lymph node status; independently, however, they are sig- 
nificant factors in predicting recurrence. 
Tumor margin as a prognostic factor has not been given 
its due importance. Lately, however, some studies]’ have 
reported this to be a significant factor in multivariate 
analysis. The tumor margin in this study has been de- 
scribed as infiltrative or circumscribed and it is a signifi- 
cant, independent predictor of recurrence in the multi- 
variate analysis of the whole group (P < 0.01), node- 
positive group (P  < 0.05), and postmenopausal group 
(P  < 0.05) of patients. 
Ploidy and the Node-Negative Group 
Axillary lymph node-negative group is one such area 
where the treatment protocols are being actively discussed 
and the line of management is changing. Recent  trial^'^"^ 
have shown a significant increase in disease-free survival 
in the node-negative group when these patients received 
adjuvant therapy. Both of the trials, however, selected a 
high-risk group on the basis of estrogen receptor (ER) 
status and only the high-risk patients received adjuvant 
therapy. 
The node-negative group was studied with a view to 
find an independent prognostic factor that could identify 
patients likely to have an early relapse. In the multivariate 
analysis, DNA content has come out to be the only sig- 
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nificant important prognostic indicator in the node-neg- 
ative group (P < 0.05). Of the 28 node-negative tumors 
nine were diploid and 19 were nondiploid. Eight of 19 
nondiploid tumors (42%) recurred whereas there were no 
recurrences in the diploid group. This shows the advantage 
of using ploidy analysis in identifying a group within the 
node-negative group that is more likely to recur. This 
prognostic indicator could be used to select a group that 
may benefit from adjuvant therapy. 
It is concluded that nuclear DNA content is an objective 
marker of tumor aggressiveness and can significantly en- 
hance our prognostic capabilities. This can also help in 
defining subsets of patients with a high probability of short- 
term relapse especially in the node-negative group, thus 
making them candidates for adjuvant therapy. 
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